
[Cancer Research 52, 1525-1529, March 15, 1992]
© 1992 American Association for Cancer Research
Tumor-promoting Phorbol Ester Down-Regulates the Androgen Induction of Prostate-specific Antigen in a Human Prostatic Adenocarcinoma Cell Line1
P. E. Andrews,
C. Y-F. Young2,
B. T. Montgomery and
D. J. Tindall
Departments of Urology [P.E.A., C.Y.-F.Y., B.T.M., D.J.T.] and Biochemistry and Molecular Biology [D.J.T.], Mayo Clinic/Foundation, Rochester, Minnesota 55905
Prostate-specific antigen (PSA) is the most sensitive marker available for monitoring the progression of prostate cancer and response to therapy. In a previous study, we demonstrated tissue-specific expression of PSA glycoprotein and mRNA and its regulation through the androgen receptor. In this study, we examine the effects of protein kinase A (PKA) and protein kinase C (PKC) on the androgen regulation of PSA in a human adenocarcinoma cell line, LNCaP. Northern blot analysis demonstrated that forskolin, an activator of PKA, had no effect on the androgen regulation of PSA. However, the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA), a direct activator of PKC, showed a time- and dose-dependent repression of the androgen regulation of PSA glycoprotein and mRNA. The biologically inactive phorbol ester, 4
-phorbol-12,13-didecanoate, had no effect. Staurosporine, a PKC inhibitor, blocked the TPA-mediated repression of the androgenic stimulation of PSA glycoprotein. In addition, the calcium ionophore, A21387, was able to simulate the actions of TPA, presumably through activation of PKC via calcium mobilization. In summary, the androgenic regulation of PSA protein and mRNA is repressed by tumor-promoting phorbol esters through the PKC pathway. This indicates that the effects of TPA may be secondary to repressed gene transcription or altered mRNA stability. In addition, this study emphasizes that the androgenic regulation of PSA is complex and may involve other extracellular transduction signals.
1 Supported in part by NIH Grants CA32387, HO09140, and DK41995.
2 To whom requests for reprints should be addressed.
Received 8/ 9/91.
Accepted 1/ 9/92.
This article has been cited by other articles:

|
 |

|
 |
 
S. Periyasamy, M. Warrier, M. P. M. Tillekeratne, W. Shou, and E. R. Sanchez
The Immunophilin Ligands Cyclosporin A and FK506 Suppress Prostate Cancer Cell Growth by Androgen Receptor-Dependent and -Independent Mechanisms
Endocrinology,
October 1, 2007;
148(10):
4716 - 4726.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pospisil, K. Wang, A. F. Al Aowad, L. K. Iyer, S. J. Adelstein, and A. I. Kassis
Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors
Cancer Res.,
March 1, 2007;
67(5):
2197 - 2205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Guo, C. Jiang, Z. Wang, H.-J. Lee, H. Hu, B. Malewicz, H.-J. Lee, J.-H. Lee, N.-I. Baek, J.-H. Jeong, et al.
A novel class of pyranocoumarin anti-androgen receptor signaling compounds
Mol. Cancer Ther.,
March 1, 2007;
6(3):
907 - 917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Jiang, H.-J. Lee, G.-x. Li, J. Guo, B. Malewicz, Y. Zhao, E.-O. Lee, H.-J. Lee, J.-H. Lee, M.-S. Kim, et al.
Potent Antiandrogen and Androgen Receptor Activities of an Angelica gigas-Containing Herbal Formulation: Identification of Decursin as a Novel and Active Compound with Implications for Prevention and Treatment of Prostate Cancer
Cancer Res.,
January 1, 2006;
66(1):
453 - 463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Rigas, D. M. Ozanne, D. E. Neal, and C. N. Robson
The Scaffolding Protein RACK1 Interacts with Androgen Receptor and Promotes Cross-talk through a Protein Kinase C Signaling Pathway
J. Biol. Chem.,
November 14, 2003;
278(46):
46087 - 46093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gioeli, S. B. Ficarro, J. J. Kwiek, D. Aaronson, M. Hancock, A. D. Catling, F. M. White, R. E. Christian, R. E. Settlage, J. Shabanowitz, et al.
Androgen Receptor Phosphorylation. REGULATION AND IDENTIFICATION OF THE PHOSPHORYLATION SITES
J. Biol. Chem.,
August 2, 2002;
277(32):
29304 - 29314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Xing, Y. Chen, S. H. Mitchell, and C. Y.F. Young
Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
Carcinogenesis,
March 1, 2001;
22(3):
409 - 414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Sadar
Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways
J. Biol. Chem.,
March 19, 1999;
274(12):
7777 - 7783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. I. Scher, W. M. K. Kelly, Z.-F. Zhang, P. Ouyang, M. Sun, M. Schwartz, C. Ding, W. Wang, I. D. Horak, and A. B. Kremer
Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
J Natl Cancer Inst,
February 3, 1999;
91(3):
244 - 251.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1992 by the American Association for Cancer Research.